Purpose: Benzalkonium chloride (BAK) is the most commonly found preservative in eye drops, and has been shown to cause ocular surface inflammation and toxicity. Lacritin is a human tear glycoprotein secreted from the lacrimal glands that has been found to be cytoprotective. This study was designed to determine if the presence of lacritin confers protection to a cultured human corneal epithelial (HCE) cell line, CRL-11515, and primary HCE cells after exposure to the ocular preservative agent BAK. Materials and methods: Recombinant human lacritin was cloned into intein fusion vectors, expressed in E. coli, and purified on chitin beads and DEAE Sepharose. Metabolic curves were established using the MTT assay after exposure of sub-confluent CRL-11515 cells to BAK or lacritin. Western blot analysis of lipidated LC3 (LC3-II) provided a measure of autophagy in CRL-11515 cells exposed to lacritin and/or BAK. Results: BAK reduced CRL-11515 cellular metabolic activity in a time-and dose-dependent manner. BAKinduced cellular stress was evident by elevated autophagy that increased with rising concentrations of BAK compared to control (p50.05). Lacritin increased HCE cell proliferation at an optimal dose of 1 nM. Preconditioning HCE cells with 1 nM lacritin for 24 h prior to BAK exposure significantly dampened levels of LC3-II (p50.05) and promoted a significant increase in cellular metabolic activity (p50.01) compared to BAK alone. Conclusions: These results suggest lacritin protects cultured HCE cells stressed with BAK. Lacritin may have the potential to be used as a topical adjunctive therapy in eyes chronically exposed to BAK.
INTRODUCTION
Many topical medications for ophthalmic use have documented surface toxicity. This often leads to significant patient morbidity, and occasionally, the discontinuation of medications despite therapeutic benefits. For chronic diseases like glaucoma, lack of compliance due to cessation of topical medical therapy can result in irreversible visual loss. Surface toxicity can be attributed, in part, to preservatives found in topical medications, most commonly benzalkonium chloride (BAK).
The reported negative clinical effects of BAK include photophobia, hyperemia, corneal edema, punctuate keratitis, gray corneal epithelial haze, pseudomembrane formation, and toxicity to corneal cells. 1 BAK has been found to cause damage by several mechanisms including promoting inflammation and mediating cell death. Human corneal and conjunctival cells demonstrated significant induction of tumor necrosis factor-alpha (TNF-a), an inflammatory biomarker, after exposure to low doses of BAK. 2 BAK has also been reported to cause apoptosis of conjunctival 3 and corneal cells; 4 at higher concentrations, cell death can also occur via necrosis. 3, 4 BAK can remain in ocular tissues up to 48 h after application 1 and has a cumulative effect. 3 Therefore, a patient on chronic eye drops, such as a typical glaucoma patient, is more likely to experience toxicity than an individual only requiring acute and temporary therapy.
Lacritin is a secreted glycoprotein from acinar cells of the human lacrimal gland and is also expressed by conjunctival and corneal epithelial cells. 5, 6 Being in the tear film, it has been under investigation for its protective properties on the corneal epithelium. 7, 8 This natural tear molecule behaves as an ocularspecific prosecretory mitogen by stimulating basal lacrimation in rat lacrimal acinar cells. 9 In addition, lacritin promotes human corneal epithelial (HCE) cell homeostasis 10 and stimulates HCE proliferation. 8 Evidence has also been presented for selective lacritin downregulation in tears of patients with contact lensrelated dry eye, 11 blepharitis, 12 and Sjö gren's syndrome, 13 suggesting that the presence of lacritin is integral to maintaining a healthy ocular surface.
Autophagy is a cellular process critical in maintaining homeostasis under physiological conditions. However, excessive autophagy contributes to cell injury and death. 14, 15 It is not known whether lacritin protects HCE cells from BAK-induced cytotoxicity. The present study was designed to determine whether lacritin protects against BAK-induced cell injury and autophagy in HCE cells. If lacritin is found to be cytoprotective in this application, it has the potential to be developed as a natural topical adjunctive therapy in eyes exposed to chronic stressors, such as topical preservatives. This, in turn, may have a positive influence on compliance.
MATERIALS AND METHODS

Reagents
All cell culture reagents were purchased from Invitrogen (Gibco BRL, Burlington, ON, Canada). LC3 antibodies and MTT were purchased from Sigma-Aldrich (Oakville, ON, Canada).
Cell Culture
The HCE cell line CRL-11515 was purchased from the American Type Culture Collection (Manassas, VA).
Primary HCE were purchased from Sciencell Research Laboratories (Carlsbad, CA). The lacritin DNA coding sequence was cloned into the IMPACTTM-CN vector pTYB1 (New England BioLabs, Inc., Ipswich, MA) to generate the lacritin-intein fusion plasmid ''pLAC''. Recombinant proteins were expressed in E. coli, purified on chitin beads (New England BioLabs, Inc., Ipswich, MA), and further purified on DEAE Sepharose (GE Healthcare, Little Chalfont, United Kingdom) as previously described. 13 Purified proteins were freeze-dried and stored at À80 C until use. CRL-11515 cells and primary HCE cells within five passages from the time of purchase were cultured in a Keratinocyte-Serum Free medium. They were seeded at 105 cells onto 24-well plates and grown for 24 h. BAK and lacritin experiments were initiated at 60% confluency as determined by the area of cell coverage under microscopy.
BAK Time and Dose Curves -Cellular Metabolic Activity
About 60% subconfluent CRL-11515 cells were treated with 0.004% BAK for 1, 3, 10 and 30 min. CRL-11515 cells were treated with 0.001%, 0.002%, 0.003%, 0.004% and 0.005% of BAK for 1 min. Cellular metabolic activity was subsequently assessed with the MTT assay.
Lacritin Time Curve -Cellular Metabolic Activity
In total, 60% subconfluent CRL-11515 cells were exposed to 1 nM lacritin for 1 min, 15 min, 30 min, and 24 h. Cells were then washed, and cellular metabolic activity was assessed with the MTT assay.
BAK and Lacritin -Autophagy
About 0.001% and 0.004% BAK was added to 60% subconfluent CRL-11515 cells for 1 min and autophagy was assessed using Western blot analysis to monitor levels of lipidated LC3-II. Autophagy was similarly estimated after lacritin treatment (0.1, 1, 10 nM).
Three sets of experiments were performed using BAK (0.004%) and lacritin (1 nM). Cellular metabolic activity in CRL-11515 and primary HCE cells were measured using the MTT assay. Autophagy was assessed by Western Blotting for LC3-II. 
MTT Assay
The MTT reduction assay was used as an index of cellular metabolic activity and was performed according to the manufacturer's instructions. Briefly, control and treatment groups were incubated in serum-free medium containing 0. 
Statistical Analysis
All data are given as the mean AE SD of at least three experiments. Where applicable, differences between two groups were compared by the unpaired, two-tailed Student's t-test. For multigroup comparisons, one-way ANOVA followed by Student-Newman-Keuls test was performed. p50.05 was considered statistically significant.
RESULTS
BAK-Induced Suppression of Crl-11515 Cellular Metabolic Activity is Time and Dose Dependent
BAK promoted a time ( Figure 1A ) and dose ( Figure 1B) 
Lacritin Enhanced Metabolic Activity of CRL-11515 Cells is Time Dependent
The optimal exposure time to lacritin was determined by treating CRL-11515 cells with 1 nM lacritin for 
BAK Treatment of CRL-11515 Cells Increases Autophagy
One-minute treatment with 0.004% BAK increased autophagic marker LC3-II more than treatment with 0.001% BAK (Figure 3) , consistent with decreased metabolic activity after BAK exposure (Figure 1 ). 0.004% BAK was accordingly chosen for subsequent autophagy experiments. Quantitation was performed by densitometry and expressed as the normalized ratio of LC3-II/GAPDH.
Pre-Treatment of CRL-11515 Cells with Lacritin Rescues BAK-Induced Autophagy
Lacritin itself did not show any statistically significant positive or negative effect on autophagy in the absence of BAK-induced stress (Figure 4 ). Treating CRL-11515 cells with 1 nM lacritin and 0.004% BAK simultaneously for 1 min had no statistically significant effect, however pre-incubating CRL-11515 cells with 1 nM lacritin for 24 h prior to 0.004% BAK treatment for 1 min significantly reduced LC3-II compared to 1 min 0.004% BAK treatment alone ( Figure 5 ).
Co-and Pre-Treatment of Human Corneal Epithelial Cells with Lacritin Increases Cellular Metabolic Activity
Subsequently, a series of experiments was performed combining 0.004% BAK and 1 nM lacritin to determine if pre-treating with or co-administering lacritin would partially rescue BAK-suppressed cellular metabolic activity. Adding lacritin to BAK for 1 min promoted a statistically significant increase in CRL-11515 cell metabolic activity compared to BAK alone. Pre-incubating the cells with lacritin for 24 h was also effective ( Figure 6A) . To confirm the cell line results, primary HCE cells were used and our data show that lacritin at 1 nM also had a protective effect against BAK-induced inhibition of metabolic activity in primary HCE cells ( Figure 6B ).
DISCUSSION
BAK is a preservative commonly used in multi-dose eye drops, such as those approved for the treatment of glaucoma. However, studies have shown ocular toxicity associated with BAK. 1, [16] [17] [18] [19] [20] In the present study, the MTT assay was used to measure NADPHdependent cellular oxioreductase enzyme activity, which reflects mitochondrial activity and cell viability. 21 Even at the lowest concentration tested, 0.001%, there was significant loss of cellular metabolic activity, and we demonstrated that this decrease in cellular metabolic activity was present even at short exposure times. The concentration range of BAK in topical agents is typically between 0.004% and 0.025%, 22 up to 25 times higher than the lowest concentration employed in this study. In addition, since the half-life of BAK is 20 h in corneal epithelial tissues, 23 this may cause prolonged damage to the ocular surface in patients chronically using eye drops. However, BAK is still used in ophthalmic drops because preservative free eye drops are at risk of contamination, which can lead to serious ocular infections. 24, 25 Thus, it is important to find an agent that protects against BAK toxicity. The present study was designed to investigate whether lacritin is capable of protecting the ocular surface from the cytotoxic effects of BAK.
Lacritin has both prosecretory and mitogenic properties and it is selectively down-regulated in dry eye. However, the effect of lacritin on BAKinduced cytotoxicity has not been established. In the present study, we demonstrated lacritin alone increases cellular metabolic activity of HCE cells in a biphasic manner. Concomitant and pre-treatment with lacritin and BAK significantly increased cellular metabolic activity compared to HCE cells treated with BAK alone. Our results suggest that lacritin increases cellular viability and protects HCE cells from BAKinduced cellular toxicity.
Autophagy is a cellular process in which damaged or dysfunctional organelles and protein aggregates are removed by the formation of autophagosomes, which requires the participation of autophagy-related proteins and microtubule-associated protein light chain 3-II (LC3-II). 14, 15 The level of autophagy is tightly controlled to achieve cellular homeostasis. However, massive induction of autophagy may promote cell death and injury. It has been shown that BAK induces excessive autophagy of conjunctival epithelial cells. 26 Notably, lacritin increases LC3-II degradation in human corneal epithelial cells stressed with interferon-g and TNF-a. 10 To our knowledge, it is not known whether BAK induces autophagy in human corneal epithelial cells. Our data showed that BAK increases LC3-II expression, indicating activation of autophagy. Interestingly, lacritin alone does not significantly alter LC3-II expression in HCE cells. Notably, pre-treatment with lacritin for 24 h decreased LC3-II expression induced by BAK. Our data suggests that lacritin inhibits autophagy induced by BAK in HCE cells.
We chose to use an immortalized cell line in our study to avoid inconsistency that occurs in primary corneal epithelial cultures due to replicative genetic changes. 27 We employed the CRL-11515 immortalized cell line, which has the advantage of displaying the same cytotoxic response as primary cultured HCE cells to eight b-blockers including propranolol, alprenolol, and metoprolol. 28 However, parallel experiments conducted using primary HCE cells showed the same results, indicating that the protective effects of lacritin are not an anomaly of the CRL-11515 immortalised cell line.
In summary, this study has shown that lacritin offers protection to cultured HCE cells stressed with BAK. Lacritin increased cell viability and reduced autophagy during BAK administration. BAK is a common preservative found in eye drops, and has been shown to cause ocular surface toxicity in patients frequently using multi-dose eye drops. Our study suggests lacritin has the potential to be a natural topical adjunctive therapy and possibly increase compliance in patients using eye drops that contain BAK.
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